(Q44193697)

30 November 2017

title

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation (English)

1 reference

30 November 2017

1 reference

1 reference

1 reference

Chuan-Mo Lee

1

1 reference

30 November 2017

Guan-Yeow Ong

2

1 reference

30 November 2017

Sheng-Nan Lu

3

1 reference

30 November 2017

Jing-Houng Wang

4

1 reference

30 November 2017

Chun-Ann Liao

5

1 reference

30 November 2017

Hung-Da Tung

6

1 reference

30 November 2017

Tsung-Ming Chen

7

1 reference

30 November 2017

Chi-Sin Changchien

8

1 reference

30 November 2017

publication date

1 November 2002

1 reference

30 November 2017

published in

Journal of Hepatology

1 reference

30 November 2017

volume

37

1 reference

30 November 2017

issue

5

1 reference

30 November 2017

page(s)

669-674

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Current therapeutic trends in therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Nucleoside analogues in the treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Clinical impact of lamivudine resistance in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Reactivation of chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Reactivation of viral replication in anti-HBe positive chronic HBsAg carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Severe clinical course of de novo hepatitis B infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Hepatitis B genotypes and the response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Interferon monotherapy in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900267-2

7 January 2021

10.1016/S0168-8278(02)00267-2

Identifiers

DOI

1 reference

30 November 2017

1 reference